BIOPARTNERS REMAINS POSITIVE AFTER ALPHENON CHMP RULING.BioPartners, Baar, Switzerland, a privately-owned biopharmaceuticals company has expressed disappointment that its biosimilar Interferon Alpha Interferon alpha Potent immune-defense protein; used as an anti-cancer drug. Mentioned in: Waldenström's Macroglobulinemia , Alpheon(R), had received a negative opinion from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP CHMP Committee for Medicinal Products for Human Use CHMP Cultural Heritage Management Plan CHMP Centrale Humanitaire Médico-Pharmaceutique CHMP Certified Hazardous Materials Practitioner (Institute of Hazardous Materials Managers) ). The ruling was based on questions concerning CMC (Common Messaging Calls) A programming interface specified by the XAPIA as the standard messaging API for X.400 and other messaging systems. CMC is intended to provide a common API for applications that want to become mail enabled. 1. (Characterization, Manufacturing and Control) and biosimilarity that have not yet been resolved to the extent the CHMP believes necessary for a biosimilar. BioPartners is looking forward to evaluating the EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. report and with the issues clarified, anticipates being in an even better position for resubmission. Only a few months ago BioPartners received marketing authorization for the European Union for Valtropin, a further biosimilar medicinal product from BioPartners. About BioPartners Headquartered in Baar, Switzerland, with an affiliate in Germany, BioPartners is a global biopharmaceuticals company and a leader in the emerging field of multi-source biopharmaceuticals. BioPartners' mission is to develop biosimilars and innovative formulations of "first generation" biopharmaceuticals as well as advanced delivery systems that may improve patient compliance. BioPartners is developing a comprehensive range of biopharmaceutical products that may offer life-saving therapeutic benefits across many therapeutic areas, including oncology, virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression , haematology, endocrinology and neurology. To date BioPartners has submitted two products (Valtropin, Alpheon) to the EMEA and in addition has two products in Phase III clinical trials. BioPartners is a DLJ Merchant Banking Partners DLJ Merchant Banking Partners (DLJMB) is a LBO-focused private equity firm of Credit Suisse. DLJMB has offices in New York, London and Los Angeles. External links
DLJ Donaldson, Lufkin & Jenrette Inc. DLJ Drive Like Jehu (band) DLJ Defence Laboratory Jodhpur (India) DLJ Dead Letter Journal Merchant Banking is a part of Credit Suisse private equity. BioPartners has partnered with LG Life Sciences, Ltd. - the leading pharmaceutical company in South Korea with a firm foundation in R&D - and other cutting edge companies, for the development and manufacture of its portfolio of drugs. For more information, visit http://www.BioPartners.ch. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion